- Home
- CRDF vs ATAI Comparison
CRDF vs ATAI Comparison
Compare CRDF & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ATAI
- Stock Information
- Founded
- CRDF 1999
- ATAI 2018
- Country
- CRDF United States
- ATAI Germany
- Employees
- CRDF N/A
- ATAI N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- ATAI Health Care
- Exchange
- CRDF Nasdaq
- ATAI Nasdaq
- Market Cap
- CRDF 240.2M
- ATAI 222.3M
- IPO Year
- CRDF N/A
- ATAI 2021
- Fundamental
- Price
- CRDF $3.45
- ATAI $1.46
- Analyst Decision
- CRDF Strong Buy
- ATAI Strong Buy
- Analyst Count
- CRDF 3
- ATAI 4
- Target Price
- CRDF $10.33
- ATAI $9.00
- AVG Volume (30 Days)
- CRDF 1.4M
- ATAI 1.8M
- Earning Date
- CRDF 02-27-2025
- ATAI 11-13-2024
- Dividend Yield
- CRDF N/A
- ATAI N/A
- EPS Growth
- CRDF N/A
- ATAI N/A
- EPS
- CRDF N/A
- ATAI N/A
- Revenue
- CRDF $688,000.00
- ATAI $331,000.00
- Revenue This Year
- CRDF $25.03
- ATAI $80.07
- Revenue Next Year
- CRDF N/A
- ATAI N/A
- P/E Ratio
- CRDF N/A
- ATAI N/A
- Revenue Growth
- CRDF 49.57
- ATAI N/A
- 52 Week Low
- CRDF $1.44
- ATAI $1.03
- 52 Week High
- CRDF $6.42
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- CRDF 45.05
- ATAI 50.37
- Support Level
- CRDF $3.33
- ATAI $1.36
- Resistance Level
- CRDF $4.89
- ATAI $1.50
- Average True Range (ATR)
- CRDF 0.31
- ATAI 0.15
- MACD
- CRDF -0.15
- ATAI -0.01
- Stochastic Oscillator
- CRDF 10.56
- ATAI 35.71
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.